@article{TAU994,
author = {Helen Boyle},
title = {Tivozanib: a novel VGFR inhibitor for kidney cancer},
journal = {Translational Andrology and Urology},
volume = {2},
number = {2},
year = {2012},
keywords = {},
abstract = {Treatment of kidney cancer has changed over the past 10 years with the approval of several targeted agents. These drugs are given on a long term base and toxicity is an issue for most patients. Despite improvement compared to immunotherapy, most patients will progress on these drugs. There is a need for more portent and better tolerated drugs. Tivozanib is a potent pan VEGR specific inhibitor. In this phase II trial it gave interesting results with an overall median PFS throughout the study of 11.7 months (95% IC: 8.3-14.3 months) and an overall objective response rate of 24% (95% IC: 19-30%). “Off”-target toxicity was mild.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/994}
}